| scholarly article | Q13442814 |
| P50 | author | Maria G. Castro | Q38359288 |
| P2093 | author name string | Lowenstein PR | |
| Thomas CE | |||
| Birkett D | |||
| Anozie I | |||
| P433 | issue | 1 | |
| P921 | main subject | Adenoviridae | Q193447 |
| cytotoxicity | Q246181 | ||
| P304 | page(s) | 36-46 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain | |
| P478 | volume | 3 |
| Q90283465 | A method for gene knockdown in the retina using a lipid-based carrier |
| Q37406976 | AAV for pain: steps towards clinical translation |
| Q44477381 | Adenoviral gene vector tethering to nanoparticle surfaces results in receptor-independent cell entry and increased transgene expression |
| Q42910583 | Adenoviral-mediated Cre expression effectively suppresses GlyT1 binding in the thalamic area of GlyT1 conditional knock-out mice |
| Q36172992 | Adenoviral-mediated gene transfer into the canine brain in vivo |
| Q39682986 | Adenovirus binding to the coxsackievirus and adenovirus receptor or integrins is not required to elicit brain inflammation but is necessary to transduce specific neural cell types |
| Q42613158 | Adenovirus expression of IL-1 and NF-kappaB inhibitors does not inhibit acute adenoviral-induced brain inflammation, but delays immune system-mediated elimination of transgene expression. |
| Q45856841 | Baculoviruses exhibit restricted cell type specificity in rat brain: a comparison of baculovirus- and adenovirus-mediated intracerebral gene transfer in vivo |
| Q92086199 | Bioengineering hemophilia A-specific microvascular grafts for delivery of full-length factor VIII into the bloodstream |
| Q38287249 | Central nervous system delivery of helper-dependent canine adenovirus corrects neuropathology and behavior in mucopolysaccharidosis type VII mice. |
| Q34193457 | Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain |
| Q39524681 | Combining glial cell line-derived neurotrophic factor gene delivery (AdGDNF) with L-arginine decreases contusion size but not behavioral deficits after traumatic brain injury |
| Q44204771 | Conditional expression of the tumor suppressor p16 in a heterotopic glioblastoma model results in loss of pRB expression |
| Q35095713 | Current and future strategies for the treatment of malignant brain tumors. |
| Q33641230 | Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging |
| Q35225590 | Delivery of full-length factor VIII using a piggyBac transposon vector to correct a mouse model of hemophilia A. |
| Q44204170 | Effects of combining electrical stimulation with BDNF gene transfer on the regeneration of crushed rat sciatic nerve |
| Q36658314 | Efficacy of nonviral gene transfer in the canine brain |
| Q40548342 | Efficient delivery and stable gene expression in a hematopoietic cell line using a chimeric serotype 35 fiber pseudotyped helper-dependent adenoviral vector |
| Q45877559 | Enhanced adenovirus transduction of hMSCs using 3D hydrogel cell carriers. |
| Q36464407 | Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system |
| Q33364523 | Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice. |
| Q47318878 | Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients |
| Q40378943 | Ex vivo nonviral gene delivery of μ-opioid receptor to attenuate cancer-induced pain |
| Q34069598 | Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology |
| Q36994063 | Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits. |
| Q45122755 | Functional applications of novel Semliki Forest virus vectors are limited by vector toxicity in cultures of primary neurons in vitro and in the substantia nigra in vivo |
| Q36367568 | Gene Therapy for the Treatment of Neurological Disorders: Central Nervous System Neoplasms. |
| Q33917592 | Gene delivery with viral vectors for cerebrovascular diseases |
| Q37994717 | Gene therapy approaches for lysosomal storage disorders, a good model for the treatment of mendelian diseases |
| Q35045240 | Gene therapy for cerebral vascular disease: update 2003. |
| Q35074544 | Gene therapy for pituitary tumors: from preclinical models to clinical implementation |
| Q35340196 | Gene therapy for the nervous system: challenges and new strategies |
| Q43157946 | Gene transfer into neural cells in vitro using adenoviral vectors |
| Q33904294 | Gene transfer into rat brain using adenoviral vectors. |
| Q34375860 | Genetic engineering within the adult brain: implications for molecular approaches to behavioral neuroscience |
| Q28277560 | Gutless adenovirus: last-generation adenovirus for gene therapy |
| Q44420163 | HSV-1 VP22 augments adenoviral gene transfer to CNS neurons in the retina and striatum in vivo |
| Q40883683 | Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo |
| Q64376671 | Hes1 negatively regulates neurogenesis in the adult mouse dentate gyrus following traumatic brain injury |
| Q45884040 | High-capacity, helper-dependent, "gutless" adenoviral vectors for gene transfer into brain |
| Q45858691 | Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area. |
| Q36045396 | Immune problems in central nervous system cell therapy. |
| Q42861412 | Immune regulation of transgene expression in the brain: B cells regulate an early phase of elimination of transgene expression from adenoviral vectors |
| Q36498773 | Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions |
| Q36274402 | Immunological thresholds in neurological gene therapy: highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cells. |
| Q36498768 | Immunology of neurological gene therapy: how T cells modulate viral vector-mediated therapeutic transgene expression through immunological synapses |
| Q34658351 | Impact of E1 and Cre on adenovirus vector amplification: developing MDCK CAV-2-E1 and E1-Cre transcomplementing cell lines. |
| Q33216908 | In vivo transgene expression from an adenoviral vector is altered following a 6-OHDA lesion of the dopamine system. |
| Q35131222 | Inflammation and adaptive immune responses to adenoviral vectors injected into the brain: peculiarities, mechanisms, and consequences |
| Q34546483 | Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. |
| Q40483395 | Lentiviral-mediated delivery of Bcl-2 or GDNF protects against excitotoxicity in the rat hippocampus |
| Q45875626 | Magnetic nanoparticles enhance adenovirus transduction in vitro and in vivo |
| Q40485805 | Medial hypothalamic 5-hydroxytryptamine (5-HT)1A receptors regulate neuroendocrine responses to stress and exploratory locomotor activity: application of recombinant adenovirus containing 5-HT1A sequences. |
| Q35131213 | Molecular basis of the inflammatory response to adenovirus vectors |
| Q37998570 | Molecular neurosurgery: vectors and vector delivery strategies |
| Q34135050 | Molecular therapy in a model neuroendocrine disease: developing clinical gene therapy for pituitary tumours. |
| Q34074765 | Neuronal expression of the transcription factor Gli1 using the Talpha1 alpha-tubulin promoter is neuroprotective in an experimental model of Parkinson's disease. |
| Q40630598 | Neurotrophic factors expressed in both cortex and spinal cord induce axonal plasticity after spinal cord injury |
| Q52549450 | Neurotrophin-3 expressed in situ induces axonal plasticity in the adult injured spinal cord. |
| Q33985663 | Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders |
| Q36411432 | Novel siRNA formulation to effectively knockdown mutant p53 in osteosarcoma |
| Q36498762 | One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications. |
| Q35870480 | Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro |
| Q92678385 | Optimization of an ex vivo gene transfer to the hamstrings tendons muscle remnants: potential for genetic enhancement of bone healing |
| Q42442484 | Optimization of transgene expression at the posttranscriptional level in neural cells: implications for gene therapy |
| Q40557969 | Optimized lentiviral vector production and purification procedure prevents immune response after transduction of mouse brain |
| Q34365087 | Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity |
| Q44426809 | Prevention of the initial host immuno-inflammatory response determines the long-term survival of encapsulated myoblasts genetically engineered for erythropoietin delivery |
| Q35120176 | Progress and problems with the use of viral vectors for gene therapy |
| Q35069550 | Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction. |
| Q42022920 | Rapid upregulation of interferon-regulated and chemokine mRNAs upon injection of 108 international units, but not lower doses, of adenoviral vectors into the brain |
| Q33985688 | Recent advances in the pharmacology of neurological gene therapy |
| Q38085469 | Recent gene therapy advancements for neurological diseases. |
| Q36569912 | Regulatable gene expression systems for gene therapy |
| Q36157542 | Regulatable gene expression systems for gene therapy applications: progress and future challenges |
| Q34233124 | Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. |
| Q37403279 | Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity |
| Q52552384 | Restoration of an impaired TGF-beta1 autocrine growth-inhibitory circuit results in growth inhibition of ovarian epithelial cancer cells and complete inhibition of their tumorigenicity. |
| Q36534329 | Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trial |
| Q40413612 | Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses |
| Q35999648 | Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation. |
| Q41189810 | The Long and Winding Road: From the High-Affinity Choline Uptake Site to Clinical Trials for Malignant Brain Tumors |
| Q97646315 | Transient Chimeric Ad5/37 Fiber Enhances NK-92 Carrier Cell-Mediated Delivery of Oncolytic Adenovirus Type 5 to Tumor Cells |
| Q37946113 | Viral vectors for gene delivery to the central nervous system |
| Q36960666 | Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production. |
| Q33894621 | Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS |
| Q44576921 | Widespread distribution of beta-hexosaminidase activity in the brain of a Sandhoff mouse model after coinjection of adenoviral vector and mannitol. |
| Q38461882 | pUNISHER: a high-level expression cassette for use with recombinant viral vectors for rapid and long term in vivo neuronal expression in the CNS. |
Search more.